Lonza acquires five CDMO manufacturing sites and approximately 1,100 highly skilled employees, more than doubling its US footprint to nine CDMO sites with a US workforce of more than 6,000 employees. Transaction will strengthen Lonza’s end-to-end…
-
Lonza acquires five CDMO manufacturing sites and approximately 1,100 highly skilled employees, more than doubling its US footprint to nine CDMO sites with a US workforce of more than 6,000 employees.
-
Transaction will strengthen Lonza’s end-to-end offering in the US, adding clinical and commercial development and manufacturing capabilities for bioconjugation, payload-linkers1 and viral vectors.
-
Lonza will acquire the assets and associated businesses at a total enterprise valuation in the low- to mid-triple-digit millions Swiss francs.
-
Lonza’s financial outlook for 2026 and the Organic Growth Model, including associated financial mid-term ambitions, are confirmed.
Basel, Switzerland, 3 November 2026 – Lonza, the world’s leading contract development and manufacturing organization (CDMO), announced today that it has signed a definitive agreement to acquire five CDMO manufacturing sites in the US from Merck KGaA, Darmstadt, Germany at a total enterprise valuation in the low- to mid-triple-digit millions Swiss francs.
The acquisition expands Lonza’s US CDMO manufacturing footprint from four to nine sites and complements its global network by adding end-to-end development and manufacturing capabilities in the US, the largest market for innovative pharmaceuticals. The acquired network supports customers from clinical through to commercial in attractive growth areas such as antibody-drug conjugates (ADCs) and other bioconjugates, viral vectors for cell & gene therapies and advanced drug-delivery technologies. Together with the ongoing investment in CDMO readiness in Vacaville, California, and the recently **announced**investment in a commercial spray-drying facility in Bend, Oregon, this acquisition represents another step in building an even more comprehensive, competitive CDMO network in the US.
Wolfgang Wienand, Chief Executive Officer, Lonza, commented: “This acquisition is a strong fit with our One Lonza Strategy and reflects our disciplined approach to capital allocation, investing in opportunities that will drive long-term, profitable growth and deliver attractive returns. It will significantly expand our US presence, bringing us even closer to our customers, while increasing the resilience of our global manufacturing network. With high demand for bioconjugates and viral vectors, the acquired sites will strengthen our ability to support customers from innovation to launch and commercial supply. I am particularly excited to welcome the highly experienced teams at these sites to One Lonza. It takes great people with deep scientific expertise and excellence in development and manufacturing to reliably translate breakthrough innovation into viable therapies for patients. Together, we will build an even stronger offering for our customers.”
Kai Beckmann, Chairman of the Executive Board and Group CEO, Merck KGaA, Darmstadt, Germany, commented: “Today’s announcement is another important step in advancing our mid- to long-term strategic agenda. A more concentrated Life Science portfolio will allow us to focus our investments on building our scientific leadership and make us an even stronger partner for our customers. Our CDMO teams have built a strong foundation through their expertise and commitment. We believe Lonza is well positioned to build on that foundation and support the business’s next phase of growth.”
Under the terms of the agreement, approximately 1,100 highly skilled employees will join Lonza's global workforce and increase its US employee base to more than 6,000 employees. The facilities that Lonza has agreed to acquire will expand its capabilities across the following technologies and from clinical development through to commercial manufacturing services:
-
St. Louis, Missouri: Bioconjugates.
-
Madison and Verona, Wisconsin: High-potency payload-linkers.
-
Carlsbad, California: End-to-end viral vector solutions, including aseptic fill-finish capabilities.
-
Indianapolis, Indiana: Lipid nanoparticle, liposome, and PEGylated protein solutions, including aseptic fill-finish capabilities.
In Full-Year 2028, the acquired sites are expected to contribute around CHF 250 million in sales at a CORE EBITDA margin below Lonza’s, with an insignificant impact on the group. Once integrated, the sites are expected to benefit from Lonza’s pure-play CDMO focus and deliver significant, profitable growth over time, using existing available capacities and additional expansion space, with further investments aligned with evolving market demand. Lonza anticipates the business to reach peak sales at Lonza’s future group margin level by mid-2030s.
Transaction details
Under the terms of the agreement, Lonza will acquire the five sites and associated businesses at a total enterprise valuation in in the low- to mid-triple-digit millions Swiss francs. The consideration will be paid for in cash and funded with cash at hand and Lonza’s existing credit facilities, maintaining the company’s BBB+ rating.
Closing of this transaction is expected mid-2027, subject to customary closing conditions. Lonza and Merck KGaA, Darmstadt, Germany will work closely to support a smooth transition of the businesses. Until the transaction closes, the businesses will continue to operate independently. Following closing, Lonza’s immediate priorities will include ensuring continuity for customers, supporting employees through the transition, and fully integrating the acquired operations into Lonza’s global network.
This transaction will not affect Lonza’s previously announced share buyback following the closing of the divestment of its Capsules & Health Ingredients business2.
BofA Securities is acting as financial advisor to Lonza.
For more details on the transaction, please refer to the related [Investor Presentation](https://www.lonza.com/-/media/Lonza/Lonzacom/investor-relations/Financial Presentations/20261102_investor_presentation).
Investor & Media Call Details
Lonza invites investors, analysts and journalists to join a live webcast and conference call from 09:00 to 09:45 am CET on 3 November 2026 with Wolfgang Wienand (CEO) and Philippe Deecke (CFO) who will share a short presentation on the transaction and will, together with Christian Seufert (Business Platform Head, Advanced Synthesis) and Daniel Palmacci (Business Platform Head, Specialized Modalities), take questions.
Access to webcast
In order to follow the slide presentation and the Q&A session, please use the webcast link.
Access to conference call The presentation will be followed by a Q&A session. You can register to ask questions over the conference call at any time during the event. You will receive the relevant phone numbers, a passcode and your personal PIN to access the conference call by pre-registering here.
You may also join the conference call via the new HD web phone option, directly through your browser. Simply click the HD web phone link in the confirmation email.
Should you experience any issues with registration, please use one of the numbers below or join via the HD Web Phone link. Please dial the following numbers 10 to 15 minutes prior to scheduled start:
+41 (0) 58 310 50 00 (Europe and Switzerland)
+44 (0) 203 059 5863 (UK)
+1 631 570 56 13 (USA)
Other international numbers are available here.
About Lonza
Lonza is the world’s leading contract development and manufacturing organization (CDMO) dedicated to serving the healthcare industry. Working across three continents, Lonza’s global team of approximately 17,000 colleagues3 works alongside pharma and biotech companies to turn their breakthrough innovations into viable therapies. This enables customers to bring life-saving and life-enhancing treatments to patients worldwide with a combination of cutting-edge science, smart technology and lean manufacturing.
Our company generated sales of CHF 3.4 billion with a CORE EBITDA of CHF 1.2 billion in Half-Year 2026.
Find out more at www.lonza.com.
-
High-potency
-
Closing of the divestment of the Capsules & Health Ingredients business is expected by year-end 2026.
-
For Lonza’s continuing CDMO business, excluding Capsules & Health Ingredients.
Downloads
Share
Post
Share
Email



Privacy Preference Center
When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, or your device, and is mostly used to make the site work as you expect. The information does not usually identify you directly, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. Blocking some types of cookies may impact your experience of the site and the services we are able to offer.
More information
Allow All
Manage Consent Preferences
Targeting Cookies
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Cookies Details
Strictly Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.
Cookies Details
Functional Cookies
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.
Cookies Details
Performance Cookies
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies Details
Cookie List
Clear
Apply Cancel
Leg.Interest
checkbox label label
checkbox label label
checkbox label label
Reject All

